ClinicalTrials.gg
CompletedNCT01994889ATTR-ACTUpdated Apr 24, 2019Results posted

Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

A Phase 3 interventional study of Tafamidis and Tafamidis in Transthyretin (TTR) Amyloid Cardiomyopathy, sponsored by Pfizer. Completed at 80 sites in 13 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-04-24.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
441
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Amyloid Neuropathies, Familial with a site in United States — 23 open to participants now, 26 under way, 4 of them phase 3. Amyloid Neuropathies, Familial · United States.

Enrollment
6th of 38
441 · median 53
Started
2013
with 5 others
Phase 3
14 of 58
2 open now
Registered
7th of 58
by date
Lead sponsor
3 of 58
Pfizer

Among the 58 studies in Amyloid Neuropathies, Familial with a site in United States, this one is the 6th largest by enrollment of the 38 interventional ones that give a count, is one of 6 that started in 2013, is one of 14 in phase 3, and was the 7th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

23 of the 58 studies in Amyloid Neuropathies, Familial with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Amyloid Neuropathies, Familial with a site in United States, or all of them as a file.
02

Study summary

This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.

Read the detailed description

Phase 3, multicenter, global, three-arm, parallel design, placebo-controlled, double-blind, randomized study to determine efficacy, safety and tolerability of tafamidis on clinical outcomes (all-cause mortality and frequency of cardiovascular-related hospitalizations) in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.

03

Conditions studied

  • Transthyretin (TTR) Amyloid Cardiomyopathy

Keywords

  • amyloidosis
  • amyloid
  • transthyretin
  • TTR
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medical history of Heart Failure (HF) with at least 1 prior hospitalization for HF or clinical evidence of HF (without hospitalization) manifested by signs or symptoms of volume overload or elevated intracardiac pressures (e.g., elevated jugular venous pressure, shortness of breath or signs of pulmonary congestion on x-ray or auscultation, peripheral edema) that required/requires treatment with a diuretic for improvement,
  • Evidence of cardiac involvement by echocardiography with an end-diastolic interventricular septal wall thickness > 12 mm,
  • Presence of amyloid deposits in tissue and presence of a variant TTR genotype and/or TTR precursor protein identification by immunohistochemistry, scintigraphy or mass spectrometry

Exclusion criteria

Exclusion Criteria:

  • A (NYHA) classification of IV.
  • Presence of primary (light chain) amyloidosis.
  • Prior liver or heart transplantation or implanted cardiac mechanical assist device.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
441 participants (actual)

Study arms

  • Experimental
    Tafamidis - 20 mg

    Active Treatment-Low dose

    Drug: Tafamidis

  • Experimental
    Tafamidis - 80 mg

    Active Treatment-High Dose

    Drug: Tafamidis

  • Placebo comparator
    Placebo

    Placebo control

    Drug: Placebo

Interventions

  • Tafamidis 20 mg in soft gel capsules administered once a day for 30 months

  • Tafamidis 80 mg in soft gel capsules administered once a day for 30 months

  • DrugPlacebo

    Placebo in soft gel capsules administered once a day for 30 months

06

What researchers measure

Primary outcomes

  1. Hierarchical Combination of All-Cause Mortality and Frequency of Cardiovascular-Related Hospitalizations

    All-cause mortality and frequency of cardiovascular hospitalization were analyzed using Finkelstein-Schoenfeld method. The method combines all-cause mortality and frequency of CV-related hospitalizations in a hierarchical fashion using all-cause mortality first. The method compares every participant with every other participant within strata, assigning a +1 to the "better" participant and a -1 to the "worse" participant and 0 if they are "tied". Participants who discontinued for transplantation (heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device, were handled in the same manner as death. 'Win' represents a participant doing better based on hierarchical comparison. The reported unit is the total "wins" for each treatment group from performing such a hierarchical comparison across all 4 strata in the study.

    Time frame: Baseline up to Month 30

Secondary outcomes

  1. All-Cause Mortality

    Number of deaths due to any cause was analyzed. Participants who discontinued for transplantation (heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device were handled in the same manner as death.

    Time frame: Baseline up to Month 30

  2. Frequency of Cardiovascular-Related Hospitalizations

    CV related hospitalizations per year is calculated as participant's number of CV related hospitalizations upon duration on study in years.

    Time frame: Baseline to Month 30

  3. Change From Baseline in the Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 30

    6MWT is the total distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed.

    Time frame: Baseline, Month 30

  4. Change From Baseline in Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS) at Month 30

    KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: Physical limitation, Social limitation, Quality of life, Self-efficacy, Symptom stability, Symptom frequency, Symptom burden, and Total symptoms (calculated as the mean of Symptom frequency and Symptom burden scores). Two summary scores were also calculated: Clinical Summary (calculated as mean of Physical limitation and Total symptom scores) and Overall Summary (calculated as mean of Physical limitation, Social limitation, Total symptoms, and Quality of life scores). Domain and summary scores were scaled to range from 0 (minimum) to 100 (maximum); higher scores represent better health status.

    Time frame: Baseline, Month 30

  5. Number of Participants With Cardiovascular-Related Mortality

    Deaths adjudicated as CV-related and indeterminate are reported. Participants who discontinued for transplantation (heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device, were handled in the same manner as death.

    Time frame: Baseline up to Month 30

  6. Percentage of Participants With Stabilized Transthyretin (TTR) at Month 1

    TTR stabilization is a measure of the degree of stabilization afforded the TTR molecule by tafamidis.

    Time frame: Month 1

07

Results

Posted Apr 3, 2019

Participant flow

Participant flow — Overall Study
MilestoneTafamidis 20 mgTafamidis 80 mgPlacebo
Started88176177
Completed6011385
Not completed286392
Withdrew: Adverse event51211
Withdrew: Cardiac device implantation020
Withdrew: Organ transplantation155
Withdrew: No longer willing to participate81737
Withdrew: Lost to follow-up010
Withdrew: Protocol violation011
Withdrew: Death142538

Outcome measures

PrimaryHierarchical Combination of All-Cause Mortality and Frequency of Cardiovascular-Related Hospitalizations

All-cause mortality and frequency of cardiovascular hospitalization were analyzed using Finkelstein-Schoenfeld method. The method combines all-cause mortality and frequency of CV-related hospitalizations in a hierarchical fashion using all-cause mortality first. The method compares every participant with every other participant within strata, assigning a +1 to the "better" participant and a -1 to the "worse" participant and 0 if they are "tied". Participants who discontinued for transplantation (heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device, were handled in the same manner as death. 'Win' represents a participant doing better based on hierarchical comparison. The reported unit is the total "wins" for each treatment group from performing such a hierarchical comparison across all 4 strata in the study.

Time frame:
Baseline up to Month 30
Reported as:
Number · wins
Hierarchical Combination of All-Cause Mortality and Frequency of Cardiovascular-Related Hospitalizations
winsTafamidisPlacebo
Hierarchical Combination of All-Cause Mortality and Frequency of Cardiovascular-Related Hospitalizations85955071
Statistical analysis
  • Tafamidis vs Placebo · Finkelstein-Schoenfeld Method · p = 0.0006
SecondaryAll-Cause Mortality

Number of deaths due to any cause was analyzed. Participants who discontinued for transplantation (heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device were handled in the same manner as death.

Time frame:
Baseline up to Month 30
Reported as:
Count of participants · Participants
All-Cause Mortality
ParticipantsTafamidisPlacebo
Deaths (all causes)6972
Heart transplants74
Cardiac Mechanical Assist Devices20
Statistical analysis
  • Tafamidis vs Placebo · Cox proportional hazards model · p = 0.0259 · Hazard ratio (hr): 0.698 · 95% CI 0.508 to 0.958Hazard ratio from a Cox proportional hazards model with treatment, TTR genotype (variant and wild-type) and New York Heart Association (NYHA) baseline classification (NYHA Classes I and II combined and NYHA Class III) in the model.
SecondaryFrequency of Cardiovascular-Related Hospitalizations

CV related hospitalizations per year is calculated as participant's number of CV related hospitalizations upon duration on study in years.

Time frame:
Baseline to Month 30
Reported as:
Mean · CV hospitalization per year
Frequency of Cardiovascular-Related Hospitalizations
CV hospitalization per yearTafamidisPlacebo
Frequency of Cardiovascular-Related Hospitalizations0.999 ± 2.27770.884 ± 1.2032
Statistical analysis
  • Tafamidis vs Placebo · Poisson regression analysis · p = <0.0001 (Poisson regression analysis with treatment, TTR genotype, NYHA baseline classification, treatment-by-TTR genotype interaction, and treatment-by-NYHA baseline classification interaction terms as factors adjusted for treatment duration.) · Risk ratio (rr): 0.6761 · 95% CI 0.5639 to 0.8107
SecondaryChange From Baseline in the Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 30

6MWT is the total distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed.

Time frame:
Baseline, Month 30
Reported as:
Mean · meters
Change From Baseline in the Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 30
metersTafamidisPlacebo
Baseline350.55 ± 121.296353.26 ± 125.983
Change at Month 30-30.46 ± 87.886-89.67 ± 105.159
Statistical analysis
  • Tafamidis vs Placebo · Mixed Model Repeated Measures ANCOVA · p = <.0001 · Least square mean difference: 75.68 · 95% CI 57.56 to 93.80
SecondaryChange From Baseline in Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS) at Month 30

KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: Physical limitation, Social limitation, Quality of life, Self-efficacy, Symptom stability, Symptom frequency, Symptom burden, and Total symptoms (calculated as the mean of Symptom frequency and Symptom burden scores). Two summary scores were also calculated: Clinical Summary (calculated as mean of Physical limitation and Total symptom scores) and Overall Summary (calculated as mean of Physical limitation, Social limitation, Total symptoms, and Quality of life scores). Domain and summary scores were scaled to range from 0 (minimum) to 100 (maximum); higher scores represent better health status.

Time frame:
Baseline, Month 30
Reported as:
Mean · units on a scale
Change From Baseline in Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS) at Month 30
units on a scaleTafamidisPlacebo
Baseline67.274 ± 21.356165.898 ± 21.7357
Change at Month 30-3.855 ± 19.3075-14.637 ± 21.4078
Statistical analysis
  • Tafamidis vs Placebo · Mixed Model Repeated Measures ANCOVA · p = <.0001 · Ls mean difference: 13.65 · 95% CI 9.48 to 17.83
SecondaryNumber of Participants With Cardiovascular-Related Mortality

Deaths adjudicated as CV-related and indeterminate are reported. Participants who discontinued for transplantation (heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device, were handled in the same manner as death.

Time frame:
Baseline up to Month 30
Reported as:
Count of participants · Participants
Number of Participants With Cardiovascular-Related Mortality
ParticipantsTafamidisPlacebo
Number of Participants With Cardiovascular-Related Mortality6463
Statistical analysis
  • Tafamidis vs Placebo · Cox proportional hazards model · p = 0.0383 · Hazard ratio (hr): 0.691 · 95% CI 0.488 to 0.980Hazard ratio from a Cox proportional hazards model with treatment, TTR genotype (variant and wild-type) and NYHA baseline classification (NYHA Classes I and II combined and NYHA Class III) in the model.
SecondaryPercentage of Participants With Stabilized Transthyretin (TTR) at Month 1

TTR stabilization is a measure of the degree of stabilization afforded the TTR molecule by tafamidis.

Time frame:
Month 1
Reported as:
Number · percentage of participants
Percentage of Participants With Stabilized Transthyretin (TTR) at Month 1
percentage of participantsTafamidisPlacebo
Percentage of Participants With Stabilized Transthyretin (TTR) at Month 186.13.5
Statistical analysis
  • Tafamidis vs Placebo · Chi-squared · p = <0.0001

Adverse events

Collected over Baseline up to 28 days after last dose of study drug (Month 31). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tafamidis 20 mg23/88 (26.1%)66/88 (75%)86/88 (97.7%)
Tafamidis 80 mg49/176 (27.8%)133/176 (75.6%)170/176 (96.6%)
Placebo72/177 (40.7%)140/177 (79.1%)171/177 (96.6%)
Most frequent serious events
Showing 10 of 312
Most frequent serious events
EventTafamidis 20 mgTafamidis 80 mgPlacebo
Cardiac failureCardiac disorders16/8834/17639/177
Cardiac failure congestiveCardiac disorders15/8820/17632/177
Cardiac failure acuteCardiac disorders4/8823/17617/177
Acute kidney injuryRenal and urinary disorders9/8813/17615/177
Atrial fibrillationCardiac disorders7/8811/1768/177
PneumoniaInfections and infestations6/8813/17612/177
FallInjury, poisoning and procedural complications5/889/1765/177
Pleural effusionRespiratory, thoracic and mediastinal disorders5/886/1764/177
SyncopeNervous system disorders0/886/17610/177
Ventricular tachycardiaCardiac disorders2/882/1767/177
Most frequent other events
Showing 10 of 867
Most frequent other events
EventTafamidis 20 mgTafamidis 80 mgPlacebo
DyspnoeaRespiratory, thoracic and mediastinal disorders21/8827/17651/177
FallInjury, poisoning and procedural complications24/8838/17640/177
DiarrhoeaGastrointestinal disorders10/8822/17639/177
Cardiac failureCardiac disorders18/8820/17633/177
NauseaGastrointestinal disorders9/8820/17636/177
Oedema peripheralGeneral disorders17/8829/17631/177
FatigueGeneral disorders16/8829/17633/177
DizzinessNervous system disorders16/8825/17632/177
CoughRespiratory, thoracic and mediastinal disorders16/8820/17630/177
Atrial fibrillationCardiac disorders13/8828/17631/177

Baseline characteristics

The intent-to-treat (ITT) analysis set included all participants in the safety population (all randomized participants who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation ( post baseline hospitalization, study visit, or date of death).

Age, Continuous
Age, Continuous(years)Tafamidis 20 mgTafamidis 80 mgPlaceboTotal
Mean73.3 ± 7.0775.2 ± 7.2474.1 ± 6.6974.3 ± 7.01
Sex: Female, Male
Sex: Female, Male(Participants)Tafamidis 20 mgTafamidis 80 mgPlaceboTotal
Female5182043
Male83158157398
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tafamidis 20 mgTafamidis 80 mgPlaceboTotal
Hispanic or Latino34714
Not Hispanic or Latino84171170425
Unknown or Not Reported1102
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tafamidis 20 mgTafamidis 80 mgPlaceboTotal
American Indian or Alaska Native0000
Asian211518
Native Hawaiian or Other Pacific Islander0000
Black or African American11262663
White75136146357
More than one race0000
Unknown or Not Reported0303
08

Study locations

80 sites
  • The Kirklin Clinic
    Birmingham, Alabama 35249, United States
  • UAB Hospital Department of Pharmacy IDS
    Birmingham, Alabama 35249, United States
  • University Hospital, University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • Mayo Clinic Arizona - Mayo Clinic Speciality Building
    Phoenix, Arizona 85054, United States
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • Mayo Clinic Arizona - Mayo Clinic Building
    Scottsdale, Arizona 85259, United States
  • UCSD Clinical and Translational Research Institute, Investigational Drug Service
    La Jolla, California 92037-0620, United States
  • Altman Clinical Translational Research institute
    La Jolla, California 92037-0990, United States
  • Altman Clinical Translational Research Institute
    La Jolla, California 92037, United States
  • UCSD Sulpizio Cardiovascular Center
    La Jolla, California 92037, United States
  • Cedars-Sinai Medical Center, Investigational Drug Pharmacy Services
    Los Angeles, California 90048, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Cedars-Sinai Medical Care Foundation
    Los Angeles, California 90211, United States
  • UCSF Cardiovascular Care and Prevention Center
    San Francisco, California 94143, United States
  • Stanford University Hospital and Clinics
    Stanford, California 94305, United States
  • UM Sylvester at Deerfield Beach
    Deerfield Beach, Florida 33442, United States
  • University of Miami Hospital & Clinics
    Miami, Florida 33136, United States
  • Northwestern Medical Group
    Chicago, Illinois 60611, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Advocate Christ Medical Centre
    Oak Lawn, Illinois 60453, United States
  • Ochsner Medical Center
    New Orleans, Louisiana 70121, United States
  • University of Maryland, School of Medicine
    Baltimore, Maryland 21201, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • The Johns Hopkins Hospital IDS Pharmacy
    Baltimore, Maryland 21287, United States
  • Boston Medical Center - Cardiovascular Center, Outpatient Clinic
    Boston, Massachusetts 02118, United States
  • Boston Medical Center Investigational Pharmacy Services
    Boston, Massachusetts 02118, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Boston University Medical Center General Clinical Research Unit
    Boston, Massachusetts 02118, United States
  • Michigan Medicine,University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic Pharmacy Research Supp
    Rochester, Minnesota 55905, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Newark Beth Israel Medical Center
    Newark, New Jersey 07112, United States
  • New York University Hospitals
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital
    New York, New York 10029, United States
  • Mount Sinai Doctors Faculty Practice
    New York, New York 10029, United States
  • The Mount Sinai Hospital Department of Pharmacy
    New York, New York 10029, United States
  • Columbia University Medical Center Research Pharmacy
    New York, New York 10032, United States
  • Columbia University Medical Center/Clinical Cardiovascular Research Laboratory for the Elderly
    New York, New York 10034, United States
  • Duke University Health System
    Durham, North Carolina 27710, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • OHSU Center for Health and Healing
    Portland, Oregon 97239, United States
  • OHSU Research Pharmacy Services
    Portland, Oregon 97239, United States
  • Oregon Health and Science University (OHSU)
    Portland, Oregon 97239, United States
  • Penn Presbyterian Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • University of Utah,Health Sciences Center
    Salt Lake City, Utah 84132, United States
  • VCU Medical Center - Ambulatory Care Clinic
    Richmond, Virginia 23298, United States
  • VCU Medical Center - Main Hospital
    Richmond, Virginia 23298, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Universitaire Ziekenhuizen Leuven
    Leuven, 3000, Belgium
  • Unidade de Pesquisa Clinica / Hospital Universitario Clementino Fraga Filho / UFRJ
    Rio de Janeiro, RJ 21941-913, Brazil
  • University of Calgary/Foothills Medical Centre
    Calgary, Alberta T2N 4Z6, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
  • Fakultni nemocnice u sv. Anny, Nemocnicni lekarna
    Brno, 656 91, Czechia
  • Nemocnice u sv. Anny v Brne
    Brno, 656 91, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 128 08, Czechia
  • Vseobecna fakultni nemocnice v Praze, Nemocnicni lekarna
    Praha 2, 12808, Czechia
  • IKEM, Ustavni lekarna
    Praha 4, 140 21, Czechia
  • IKEM
    Praha 4, 140 21, Czechia
  • Hopital Antoine Beclere
    Clamart, 92140, France
  • CHU Henri Mondor
    Creteil, 94010, France
  • Medical University of Heidelberg
    Heidelberg, 69120, Germany
  • Universitaetsklinikum Muenster
    Muenster, 48149, Germany
  • U.O. Cardiologia- Prof. Rapezzi
    Bologna, 40138, Italy
  • Unita Operativa di Cardiologia
    Brescia, 25123, Italy
  • S.O.D. Cardiologia Generale 1 - D.A.I. del Cuore e dei Vasi
    Firenze, 50134, Italy
  • Centro per lo Studio e la Cura Delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico S. Matteo
    Pavia, 27100, Italy
  • Kurume University Hospital
    Kurume-shi, Fukuoka 830-0011, Japan
  • Kumamoto University Hospital
    Kumamoto-city, Kumamoto 8608556, Japan
  • Shinshu University Hospital
    Nagano, 390-8621, Japan
  • University Medical Center Groningen
    Groningen, 9713 GZ, Netherlands
  • Hospital Universitario Puerta De Hierro - Majadahonda
    Majadahonda, Madrid 28222, Spain
  • Hospital Clinico Universitario Virgen de la Arrixaca
    El Palmar, Murcia 30120, Spain
  • Hospital Universitario A Coruna
    A Coruna, 15006, Spain
  • Medicin-Geriatrik kliniken-Skelleftea lasarett
    Skelleftea, 93186, Sweden
  • Sjukhusvägen, Akademiska sjukhuset
    Uppsala, 751 85, Sweden
  • St Bartholomew's Hospital-Barts Health NHS Trust
    London, EC1A 7BE, United Kingdom
  • St. George's Hospital (St George's Healthcare NHS Trust)
    London, SW17 0QT, United Kingdom
  • St. George's University of London
    London, SW17 0RE, United Kingdom
09

References and documents

Publications

  • Tess DA, Maurer TS, Li Z, Bulawa C, Fleming J, Moody AT. Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy. Amyloid. 2023 Jun;30(2):208-219. doi: 10.1080/13506129.2022.2145876. Epub 2022 Nov 18. PubMed 36399070 ↗
  • Rozenbaum MH, Tran D, Bhambri R, Nativi-Nicolau J. Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy. Am J Cardiovasc Drugs. 2022 Jul;22(4):445-450. doi: 10.1007/s40256-022-00526-9. Epub 2022 Mar 30. PubMed 35353352 ↗
  • Nativi-Nicolau J, Judge DP, Hoffman JE, Gundapaneni B, Keohane D, Sultan MB, Grogan M. How did transthyretin amyloid cardiomyopathy progress in patients who took placebo in the study ATTR-ACT? A plain language summary. Future Cardiol. 2022 Mar 17. doi: 10.2217/fca-2021-0150. Online ahead of print. PubMed 35297655 ↗
  • Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, Ebede B, Gundapaneni B, Li B, Sultan MB, Shah SJ. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. Circ Heart Fail. 2022 Jan;15(1):e008193. doi: 10.1161/CIRCHEARTFAILURE.120.008193. Epub 2021 Dec 20. PubMed 34923848 ↗
  • Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Sultan MB, Maurer MS. Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary. Future Cardiol. 2022 Mar;18(3):165-172. doi: 10.2217/fca-2021-0095. Epub 2021 Nov 15. PubMed 34779246 ↗
  • Rozenbaum MH, Garcia A, Grima D, Tran D, Bhambri R, Stewart M, Li B, Heeg B, Postma M, Masri A. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies. Eur Heart J Qual Care Clin Outcomes. 2022 Aug 17;8(5):529-538. doi: 10.1093/ehjqcco/qcab031. PubMed 33895806 ↗
  • Vong C, Boucher M, Riley S, Harnisch LO. Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis. Am J Cardiovasc Drugs. 2021 Sep;21(5):535-543. doi: 10.1007/s40256-021-00464-y. Epub 2021 Mar 26. PubMed 33770392 ↗
  • Miller AB, Januzzi JL, O'Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, Lopez-Sendon J. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]). Am J Cardiol. 2021 Jun 1;148:146-150. doi: 10.1016/j.amjcard.2021.02.035. Epub 2021 Mar 3. PubMed 33667442 ↗
  • Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, Boman K, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. JACC Heart Fail. 2021 Feb;9(2):115-123. doi: 10.1016/j.jchf.2020.09.011. Epub 2020 Dec 9. PubMed 33309574 ↗
  • Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS. Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Am J Cardiol. 2021 Feb 15;141:98-105. doi: 10.1016/j.amjcard.2020.10.066. Epub 2020 Nov 19. PubMed 33220323 ↗
  • Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, Patterson TA, Riley S, Schwartz JH, Sultan MB, Witteles R. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021 Feb;23(2):277-285. doi: 10.1002/ejhf.2027. Epub 2020 Nov 12. PubMed 33070419 ↗
  • Li B, Alvir J, Stewart M. Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial. Cardiol Ther. 2020 Dec;9(2):535-540. doi: 10.1007/s40119-020-00179-2. Epub 2020 Jun 10. PubMed 32524297 ↗
  • Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27. PubMed 30145929 ↗
  • Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, Gundapaneni B, Hahn C, Riley S, Schwartz J, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Circ Heart Fail. 2017 Jun;10(6):e003815. doi: 10.1161/CIRCHEARTFAILURE.116.003815. PubMed 28611125 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2013 to primary completion in Feb 2018, 49 months.

Results were first posted in Apr 2019, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2013
First posted
Nov 26, 2013
StartActual
Dec 9, 2013
Primary completionActual
Feb 7, 2018
CompletionActual
Feb 7, 2018
Results first posted
Apr 3, 2019
Last update
Apr 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01994889
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 26, 2013
Start date
Dec 9, 2013
Primary completion
Feb 7, 2018
Completion
Feb 7, 2018
Results posted
Apr 3, 2019
Last update
Apr 24, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafamidis

Start the discussion